期刊
EXPERT OPINION ON EMERGING DRUGS
卷 14, 期 2, 页码 207-217出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728210902946399
关键词
antisense RNA; anti-viral drugs; fusion inhibitors; RSV; therapeutic antibodies
Although respiratory syncytial virus (RSV) was discovered > 40 years ago, treatment remains largely supportive. There are no safe and effective vaccines or specific treatments other than prophylaxis with passive antibody therapy (palivizumab). However, there are good reasons to think that the scene may soon change. As the pace of development of anti-viral drugs accelerates and optimism over vaccines increases, novel therapies are set to make a major impact in the management of this very common infection. The use and effect of such interventions are not easy to anticipate, but could ultimately include the interruption of RSV's transmission resulting in profound changes to the impact ozf RSV on human health.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据